,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['mbc']
exciting new data and, another option for hr+ mbc. first choice in endocrine-refractory disease? #asco22 #mbcaction 
Associate Director for Precision Medicine, Director of Breast Medical Oncology, Scientific Director Englander IPM @WeillCornell